Literature DB >> 7886817

Do human atrial 5-HT4 receptors mediate arrhythmias?

A J Kaumann1.   

Abstract

Since their first description five years ago, knowledge about human atrial 5-HT4 receptors has increased considerably. Progress has been facilitated by the advent of selective antagonists with high affinity for human atrial 5-HT4 receptors. The receptors have been detected in both right and left atrium where they mediate increases in contractile force. Human sinoatrial 5-HT4 receptors may mediate the tachycardia caused by 5-HT and cisapride, and 5-HT elicits arrhythmias via 5-HT4 receptors in human atrium. In this article, Alberto Kaumann suggests that 5-HT may be involved in the genesis of atrial fibrillation and associated thromboembolic stroke and that both the arrhythmia and stroke could be prevented by inhibiting 5-HT4 receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7886817     DOI: 10.1016/0165-6147(94)90058-2

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  41 in total

1.  Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines.

Authors:  J Mialet; I Berque-Bestel; P Eftekhari; M Gastineau; M Giner; Y Dahmoune; P Donzeau-Gouge; J Hoebeke; M Langlois; S Sicsic; R Fischmeister; F Lezoualc'h
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

2.  Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells.

Authors:  J Mialet; I Berque-Bestel; S Sicsic; M Langlois; R Fischmeister; F Lezoualc'h
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

3.  Treatment functional GI disease: the complex pharmacology of serotonergic drugs.

Authors:  Fabrizio De Ponti; Francesca Crema
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

4.  Fading of 5-HT4 receptor-mediated inotropic responses to 5-hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium.

Authors:  Alberto J Kaumann; Finn Olav Levy
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 5.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

6.  Exploration of the ligand binding site of the human 5-HT(4) receptor by site-directed mutagenesis and molecular modeling.

Authors:  J Mialet; Y Dahmoune; F Lezoualc'h; I Berque-Bestel; P Eftekhari; J Hoebeke; S Sicsic; M Langlois; R Fischmeister
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

7.  Comparative receptor mapping of serotoninergic 5-HT3 and 5-HT4 binding sites.

Authors:  M L López-Rodríguez; M J Morcillo; B Benhamú; M L Rosado
Journal:  J Comput Aided Mol Des       Date:  1997-11       Impact factor: 3.686

Review 8.  Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.

Authors:  Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  On the presence of serotonin in mammalian cardiomyocytes.

Authors:  Klaus Pönicke; Ulrich Gergs; Igor B Buchwalow; Steffen Hauptmann; Joachim Neumann
Journal:  Mol Cell Biochem       Date:  2012-02-25       Impact factor: 3.396

10.  Cloning, pharmacological characterisation and tissue distribution of a novel 5-HT4 receptor splice variant, 5-HT4(i).

Authors:  Trond Brattelid; Ane M Kvingedal; Kurt A Krobert; Kjetil W Andressen; Trond Bach; Marit E Hystad; Alberto J Kaumann; Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-30       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.